In a patient with ankylosing spondylitis, what are the possible causes and differential diagnosis for bicytopenia (thrombocytopenia and leukopenia)?

Bicytopenia in Ankylosing Spondylitis: Causes and Differential Diagnosis

In a patient with ankylosing spondylitis presenting with bicytopenia (thrombocytopenia and leukopenia), the most likely cause is medication-induced bone marrow suppression, particularly from disease-modifying antirheumatic drugs (DMARDs) such as sulfasalazine or methotrexate, though the disease itself rarely causes cytopenias.

Primary Considerations

Medication-Induced Cytopenias (Most Common)

The bicytopenia is most likely iatrogenic if the patient is on treatment:

• Sulfasalazine: Can cause leukopenia and thrombocytopenia through bone marrow suppression
• Methotrexate: Well-known for causing pancytopenia, though typically used only for peripheral arthritis in AS 1
• TNF inhibitors: Rarely associated with cytopenias but documented
• NSAIDs: Can occasionally cause bone marrow suppression with chronic use

Critical action: Review the complete medication list immediately, including duration of therapy and recent dose changes.

Disease-Related Hematologic Abnormalities

Ankylosing spondylitis itself has distinct hematologic patterns that differ from your presentation:

• Anemia is common (present in 28.8% of AS patients), primarily anemia of chronic disease (44.1%), combined ACD with iron deficiency (29.4%), or iron deficiency anemia (23.5%) 2
• Thrombocytosis is typical, not thrombocytopenia - platelet activation and elevated platelet counts correlate with disease activity 3, 4
• Leukopenia is NOT characteristic of AS itself

This discordance is crucial: bicytopenia with thrombocytopenia contradicts the expected hematologic profile of active AS, which typically shows elevated platelets and normal to slightly elevated white blood cell counts.

Differential Diagnosis Framework

1. Drug-Induced Bone Marrow Suppression (Highest Priority)

• Temporal relationship to medication initiation or dose escalation
• Check complete blood count trends since starting DMARDs
• Consider drug interactions potentiating myelosuppression

2. Concurrent Autoimmune Process

• Systemic lupus erythematosus: Can coexist and cause immune-mediated cytopenias
• Autoimmune lymphoproliferative syndrome: Rare but causes multilineage cytopenias
• Check ANA, anti-dsDNA, complement levels

3. Myelodysplastic Syndrome or Primary Bone Marrow Disorder

• Essential thrombocythemia has been reported with AS 5, but this causes thrombocytosis, not thrombocytopenia
• Consider if cytopenias persist after stopping offending medications
• Peripheral smear and bone marrow biopsy may be needed

4. Infection-Related

• Viral infections (EBV, CMV, HIV, hepatitis) causing bone marrow suppression
• Particularly relevant if on immunosuppressive therapy
• Check viral serologies

5. Hypersplenism

• Secondary to portal hypertension if NSAID-induced liver disease present
• Less common but consider with hepatomegaly or splenomegaly

6. Nutritional Deficiencies

• Folate deficiency (especially with methotrexate use without supplementation)
• B12 deficiency
• Though these typically cause macrocytic anemia first

Diagnostic Algorithm

Immediate steps:

1. Stop potentially offending medications - particularly DMARDs if recently started or dose-escalated
2. Obtain peripheral blood smear - assess for dysplasia, blasts, or morphologic abnormalities
3. Check reticulocyte count - distinguish production versus destruction
4. Measure inflammatory markers - CRP and ESR to assess AS disease activity 2
5. Liver and renal function - assess for organ dysfunction contributing to cytopenias
6. Viral serologies - HIV, hepatitis B/C, EBV, CMV if immunosuppressed

If cytopenias persist after stopping medications:

1. Bone marrow biopsy - essential to exclude primary marrow disorder
2. Flow cytometry - rule out lymphoproliferative disorders
3. Autoimmune workup - ANA, anti-dsDNA, direct Coombs test

Critical Pitfalls to Avoid

• Do not attribute cytopenias to AS disease activity alone - this is not a typical manifestation and warrants investigation
• Do not continue DMARDs empirically - medication-induced cytopenias can progress to life-threatening pancytopenia
• Do not miss concurrent autoimmune disease - AS can coexist with other autoimmune conditions
• Do not delay hematology referral if cytopenias are severe (platelets <50,000 or WBC <2,000) or unexplained after initial workup

The evidence shows that AS typically causes anemia and thrombocytosis, not bicytopenia with thrombocytopenia 2, 3, 4. Therefore, bicytopenia in an AS patient represents either medication toxicity or a concurrent unrelated process requiring immediate investigation and likely cessation of immunosuppressive therapy.